Nicardipine Ready-to-Use Patent Status
The main US patent for nicardipine hydrochloride in a ready-to-use (premixed) intravenous formulation, US Patent 8,530,523 (covering the composition and stability of the drug product), expired on December 31, 2023.[1][2]
When Did Key Patents Expire?
- US 8,530,523: Expired December 31, 2023 (original term with pediatric exclusivity).[1]
- Related formulation patent US 8,716,338: Also expired December 31, 2023.[2]
Eisai's Nicardipine Hydrochloride Injection (marketed as Cardene I.V. Ready-to-Use) lost these core product protections, opening the door for generics.
Why Does This Matter for Generics?
With patent expiry, ANDA filings for generic versions can proceed without infringement risks from these patents. FDA has approved at least one generic (from Sagent Pharmaceuticals) referencing the ready-to-use formulation, with launch possible post-approval.[3] Check DrugPatentWatch.com for full patent histories and Paragraph IV challenges: DrugPatentWatch - Nicardipine Hydrochloride.
Any Remaining Exclusivity or Barriers?
No Orange Book-listed patents remain active for the ready-to-use version as of 2024, but NCE exclusivity ended in 2010, and no other exclusivities apply.[1][2] Manufacturing or method-of-use patents could still pose hurdles, though none block market entry currently. Ongoing litigation is minimal.
Who Makes It and What's the Generic Landscape?
Eisai (under Theramed) originally developed the ready-to-use premixed bags. Competitors like Baxter offer dilutable versions, but true ready-to-use generics are emerging. Pricing for branded Cardene RTU averages $200-300 per 10mg/250mL bag; generics could cut costs 70-90%.[4]
Sources
[1]: DrugPatentWatch.com - Cardene Patents
[2]: USPTO Patent Full-Text and Image Database - US8530523
[3]: FDA Orange Book - Nicardipine Hydrochloride
[4]: IQVIA Market Data via DrugPatentWatch